871726-73-7

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 4,5-dihydro-1H-pyrazolo[3,4-c]pyridine-6(7H)-carboxylate is used as a building block for the synthesis of biologically active compounds due to its diverse pharmacological properties.
Used in Drug Discovery and Development:
tert-butyl 4,5-dihydro-1H-pyrazolo[3,4-c]pyridine-6(7H)-carboxylate is employed as a precursor in the development of new drugs, leveraging its anti-inflammatory, analgesic, vasodilatory, and calcium antagonist activities for potential therapeutic applications.
Used in Anti-inflammatory Applications:
Tert-butyl 4,5-dihydro-1H-pyrazolo[3,4-c]pyridine-6(7H)-carboxylate is used as an anti-inflammatory agent for its potential to modulate inflammatory responses and alleviate associated symptoms.
Used in Analgesic Applications:
As an analgesic, tert-butyl 4,5-dihydro-1H-pyrazolo[3,4-c]pyridine-6(7H)-carboxylate is used to manage pain by potentially interacting with pain receptors or pathways, providing relief from discomfort.
Used in Vasodilatory Applications:
Tert-butyl 4,5-dihydro-1H-pyrazolo[3,4-c]pyridine-6(7H)-carboxylate is used as a vasodilator to improve blood flow by relaxing the smooth muscles of blood vessel walls, which can be beneficial in treating cardiovascular conditions.
Used in Calcium Antagonist Applications:
tert-butyl 4,5-dihydro-1H-pyrazolo[3,4-c]pyridine-6(7H)-carboxylate is utilized as a calcium antagonist, potentially blocking the entry of calcium ions into cells, which can be advantageous in managing conditions related to calcium dysregulation.

Upstream product

• 871792-61-9 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 40114-49-6 1-benzyl-3-piperidone 
• 871726-72-6 4-((dimethylamino)methylene)-3-oxopiperidine-1-carboxylic acid tert-butyl ester 
• 98977-36-7 3-oxo-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1228994-66-8 1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine 
• 1616097-88-1 1-(3,4-dihydroisoquinolin-2(1H)-yl)-3-(3-(1-methyl-4,5-dihydro-1H-pyrazolo[3,4-c]pyridin-6(7H)-yl)phenoxy)propan-2-ol 

Relevant academic research and scientific papers

A Continuous Flow Strategy for the Facile Synthesis and Elaboration of Semi-Saturated Heterobicyclic Fragments

An efficient hydrogenation protocol under continuous flow conditions was developed for the synthesis of underrepresented semi-saturated bicyclic fragments containing highly sp3-rich skeletons for fragment-based drug discovery (FBDD) programs. Excellent yields were generally achieved by using Pd/C (10 % w/w) and RaNi at 25–150 °C under 4–100 bar of hydrogen pressure. The generated fragments, with appropriate physicochemical properties, present diverse hydrogen-bonding pharmacophores and useful vectors for their synthetic elaboration in the optimization stage. Successive, simple functionalizations in continuous flow were accomplished to demonstrate the opportunity to develop multi-step continuous flow synthesis of valuable starting points for FBDD campaigns. A conclusive quality control (QC) was essential to discard those structures which do not fit the typical fragment library parameters.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof:wherein Y1 is of formula (?) or formula (y):Ring Y is a 5- to 6-membered heteroaryl ring; and V4, V5, Rx, x, y, and n are as defined herein. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described